Sentence examples for boost vaccine from inspiring English sources

We propose two minimum criteria for a potentially successful heterologous vaccination strategy: (1) the boost vaccine should modify or reprogram the T-cell response to display different functional and/or phenotypic characteristics to the prevaccination response; (2) the induced T-cell response should be long lived.

Keele, B. F. et al. Adenovirus prime, Env protein boost vaccine protects against neutralization-resistant SIVsmE660 variants in rhesus monkeys.

Although HPV L1 antibodies were induced in all immunized macaques, weak antibody or T cell responses to the chimeric SHIV antigens were detected only in animals receiving the DNA prime/HPV SHIV VLP boost vaccine regimen.

We have molecularly determined the HLA class II DR and DQ gene, allele and haploype profiles in HIV-1 negative ethnic Thai recipients of an HIV-1 prime boost vaccine regimen, designed to induce neutralizing antibody (NAb) responses to HIV-1 CRF01_AE.

Could California Law To Boost Vaccine Uptake End Up Reducing It? Ah, California.

A DNA prime-modified vaccinia virus Ankara (MVA) boost vaccine has proven to be potent in eliciting antibody responses.

DNA prime and recombinant fowlpox virus (rFPV) boost vaccines were designed to express multiple HIV or SIV antigens for use in human clinical trials and in pre-clinical trials in macaques.

Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer.

Our findings highlight the potential of HIV-DNA prime HIV-MVA boost vaccines for induction of functional antibody responses and suggest this vaccine regimen and ADCC studies as potentially important new avenues in HIV vaccine development.Controlled-Trials ISRCTN90053831 The Pan African Clinical Trials Registry ATMR2009040001075080 (currently PACTR2009040001075080).

As it is believed that BCG will continue to be used as a primary vaccine for human immunization and that effective boost vaccines need to be identified, our current finding that Ad vaccine-based boosting is effective to improve protection to BCG-primed guinea pigs, is significant.

Antigen-specific antibody concentrations exceeding 100 μg/ml have been attained in humans by other malaria vaccines including RTS,S and those targeting PfAMA1 (Kester et al., 2009; Spring et al., 2009), but long-term maintenance of such high-level responses may be challenging, particularly if P. falciparum infection does not appreciably boost vaccine-induced anti-PfRH5 responses.